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Time-dependent changes in polyamine metabolism and c-Myc expression are reported in kidney of mice treated with cisplatin, a widely
used anticancer drug. We show that cisplatin significantly induces the expression of two enzymes critical to proper homeostasis of cellular
polyamines, ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SSAT). We also document the cross-talk between
signalling pathway(s) induced by cisplatin injury to renal tubules and the testosterone/androgen receptor pathway. Their interaction results in
a decrease in testosterone-induced ODC activity and ODC mRNA level, and in differential modulation of SSAT expression. Moreover,
cisplatin and antifolate CB 3717, another nephrotoxic drug examined, severalfold up-regulate expression of c-Myc mRNA, albeit with
different kinetics. However, cisplatin, contrary to CB 3717, does not induce renal hepatocyte growth factor (HGF)/c-Met expression being
without effect on HGF mRNA level and significantly down-regulating c-Met transmembrane receptor message. In conclusion, these in vivo
studies document significant cisplatin-induced modulation of polyamine biosynthesis/degradation and up-regulation of c-Myc expression,
and suggest that c-Myc transcription factor is involved in the induction of ODC in kidney injured with antifolate, but not with cisplatin.
D 2004 Elsevier B.V. All rights reserved.Keywords: Cisplatin; Antifolate CB 3717; Testosteron, cross-talk; Ornithine decarboxylase; Spermidine/spermine N1-acetyltransferase; c-Myc; HGF/c-Met
1. Introduction Although cisplatin toxicity is mainly a consequence ofCisplatin (cis-diaminodichloroplatinum) is one of the
most effective anticancer agents for the treatment of patients
with a wide spectrum of tumours. However, its usefulness in
chemotherapy is compromised by its acute nephrotoxicity,
the important dose-limiting side effect recognized both in
experimental animals and in patients treated with this
compound [1,2]. The nephrotoxic effect of cisplatin appears
to be related to its preferential uptake by the proximal
tubular cells of the inner cortex and outer medulla, espe-
cially in the S3 segment. Other segments of the renal tubule
also accumulate cisplatin, but to a smaller extent, and their
damage may also contribute to clinical nephrotoxicity [3].0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.04.003
Abbreviations: ODC, ornithine decarboxylase; SSAT, spermidine/
spermine N1-acetyltransferase; HGF, hepatocyte growth factor
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(B. Grzelakowska-Sztabert).DNA damage [4,5], the drug exerts also its toxic effects
through several other mechanisms including impairment of
mitochondria function, inhibition of protein synthesis or a
decrease in the availability of reduced glutathione to scav-
enge free reactive oxygen metabolites [6–10]. Various
antidotes that can antagonize the activity of cisplatin are
among several developed renoprotective strategies [11–16].
Polyamines, small aliphatic polycations present in all
cells, are essential for cell proliferation and differentiation
[17]. Since it is recognized that polyamines bind to DNA, a
cellular polyanion, and modify its secondary structure
including chromatin condensation and DNA-matrix associ-
ation [18], the relation between polyamine deficiency and
cisplatin toxicity appeared especially interesting. The in
vitro combination therapy studies using cisplatin and vari-
ous inhibitors of ornithine decarboxylase (ODC), and there-
fore inhibitors of polyamine biosynthesis, showed either an
additive/synergistic [19–21] or an antagonistic [22,23]
effect on the growth of tumour cell lines. Thus, it has been
reported that polyamine depletion decreases the number of
A. Stachurska et al. / Biochimica et Biophysica Acta 1689 (2004) 259–266260DNA interstrand cross-links formed by cisplatin in 9L rat
brain tumour cells in vitro [23,24]. On the other hand,
pretreatment of U-251 MG human malignant brain tumour
cells with cytotoxic polyamine analogues resulted in an
increased incorporation of cisplatin into the linker region of
the chromatin and enhancement of cisplatin cytotoxicity
[25]. Moreover, it was shown that spermine (but not
spermidine or putrescine) is able to sensitize human ovarian
carcinoma cells to cisplatin action, owing, at least in part, to
an increase in cisplatin accumulation following spermine-
modulated cell membrane permeability [26]. The differ-
ences reported above between cisplatin/polyamines relation-
ship were possibly due to the drug administration sequence
and cell line specificity.
Interestingly, the property of polyamines to interact with
DNA [27] appeared valuable in search for new, third-
generation anticancer drugs. Platinum complexes with sper-
midine differed from cisplatin and showed cytotoxic and
antiproliferative properties against some cancer cell lines
[28].
Information about the effect of cisplatin on polyamine
metabolism in vivo is scarce. Treatment of rat bearing G-XII
glioma cells with cisplatin reduced ODC activity in the
tumour to undetectable level, whereas that of spermidine/
spermine N1-acetyltransferase (SSAT) was not affected [21].
However, in organs such as thymus, kidney, skeletal muscle
or heart of cisplatin-treated rats, significant increases in
spermidine and spermine were found [29].
Studies reported in this paper show that when applied in
vivo, cisplatin strongly affects murine kidney expression of
ODC and SSAT, two crucial, rate-limiting enzymes of
polyamine biosynthesis and catabolism. We also document
that cisplatin interferes with renal polyamine metabolism
modulated by testosterone via the androgen receptor. More-
over, cisplatin spectacularly induces c-Myc expression and,
to some extent, affects hepatocyte growth factor (HGF)/c-
Met signalling in drug-injured kidneys.2. Materials and methods
2.1. Animal experimental models and drug administration
Female Swiss mice (2.5–3 months old) were injected i.p.
for the duration indicated with cisplatin (15 mg/kg) in 1%
methylcellulose or with quinazoline antifolate CB 3717
(300 mg/kg, i.p.) dissolved in phosphate-buffered saline
(PBS) adjusted with a few drops of 1 M NaOH to obtain
a final pH of 9–9.5; control mice received only methylcel-
lulose or PBS, respectively. Mice were also treated with
testosterone (5 days, 125 mg/kg, s.c.) dissolved in soybean
oil (controls received soybean oil only) or with testosterone
and cisplatin (controls received soybean oil and methylcel-
lulose). The mice were killed by cervical dislocation; the
kidneys were removed, weighed, cut into several pieces and
further used for enzyme and RNA determinations. Experi-ments on the animals were carried out in accordance with
the Polish regulations, which closely match the Convention
No. 123 of the Council of Europe.
2.2. Enzyme activities and Northern blot analysis
Kidney pieces were immediately homogenized in an
appropriate buffer and further processed for ODC [30] and
SSAT [31] activity determination or were frozen at 70j
and later used for Northern blot analysis. Total RNA was
isolated, subjected to gel electrophoresis and blotted on
nylon membranes; the levels of chosen mRNA species were
estimated as described [32]. The probes used were: EcoRI-
linearized pODC 934 plasmid containing 1.4-kb fragment of
mouse ODC cDNA, BamHI insert of pET SSAT plasmid
coding 642-bp fragment of rat SSAT cDNA, BstXI insert of
pRmet2 plasmid coding 842-bp fragment of rat c-Met
cDNA [33], 1.4-kb EcoRI insert of pRBC1 plasmid coding
fragment of rat HGF cDNA [34] and 4.8-kb XhoI/BamHI
insert of pSV c-Myc plasmid containing the second and
third exons of mouse myc gene. ODC, SSAT, c-Met, HGF
and c-Myc mRNA levels were quantitated by densitometric
scanning of the autoradiograms using a Molecular Dynam-
ics Personal Laser Densitometer (Image Quant software)
and corrected for total RNA loaded on the gels as deter-
mined by ethidium bromide staining of 28S rRNA. Protein
concentration was estimated according to the method of
Lowry [35]. The results are expressed as meanFS.D. and
the number of mice is given in parentheses. Data were
analysed statistically by the Mann–Whitney test.
2.3. Thymidine incorporation
To determine thymidine incorporation into acid-insoluble
material, the mice were given injections of [methyl-3H]thy-
midine (i.p., 10 mg/kg; 0.67 MBq/25 g) 1 h prior to
sacrifice. The kidneys were dissected and processed as
described [30].
2.4. Chemicals
All chemicals purchased from commercial sources were
of analytical grade. Testosterone was obtained from Polfa
(Jelenia Go´ra, Poland); cisplatin as cis-platinum diamine
dichlororide was from Sigma, USA. Rediprime (Random
Primer Labeling), Hybond-N, Hyperfilm-MP, [a32P]dCTP
(110 TBq/mmol), DL[1-14C]ornithine dihydrochloride (2.15
GBq/mmol), and [methyl-3H]thymidine (2.96 TBq/mmol)
were obtained from Amersham (Little Chalfont, Bucks.,
UK). [Acetyl-1-14C]CoA (1.9 GBq/mmol) was from NEN
(Boston, USA). Probes for ODC and c-Myc were kindly
provided by Dr. L. Kaczmarek from the Nencki Institute of
Experimental Biology, Warsaw, Poland; those for SSAT, c-
Met, and HGF by Dr. R.A. Casero, Jr., from the Johns
Hopkins Oncology Center Research Laboratories, Balti-
more, USA, Dr. Y. Liu from Brown University School of
Table 2
Cisplatin up-regulates ODC and SSAT expression
Cisplatin
treatment (h)
Activity (fold
increase)
P mRNA (fold
increase)
P
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Osaka University Medical School, Osaka, Japan, respec-
tively. CB 3717 was generously provided by Zeneca Phar-
maceuticals (Alderley Park, Macclesfield, Cheshire, UK).
ODC:
Control 1.00F0.46 (25) – 1.00F0.33 (17) –
6 0.51F0.35 (5) NS n.d. –
18 2.01F1.36 (5) NS n.d. –
24 6.42F4.85 (25) <0.0001 1.40F0.44 (10) <0.05
48 14.76F6.78 (22) <0.0001 1.28F0.53 (23) <0.05
72 5.83F2.90 (15) <0.001 1.10F0.54 (10) NS
SSAT:
Control 1.00F0.19 (9) – 1.00F0.12 (14) –
6 1.23F0.19 (10) <0.01 n.d.
18 1.49F0.34 (5) <0.01 n.d. –
24 2.07F0.30 (10) <0.0001 1.99F0.35 (5) <0.0001
48 2.02F0.57 (10) <0.0001 2.41F0.58 (15) <0.0001
72 2.01F0.60 (9) <0.0001 1.51F0.38 (11) <0.0001
The results are expressed as meansFS.D.; the number of mice is given in
parentheses. The data were processed by the Mann–Whitney test; P values
were calculated compared with the control. Specific activity of ODC and
SSAT in kidneys of control mice is equal to 0.61F0.30 (5) and 0.48F0.15
(9) nmol/h/mg protein, respectively; NS—not significant; n.d.—not3. Results
3.1. Characteristic of cisplatin-injured mouse kidney model
Cisplatin, when applied at high dose, accumulates in
epithelial cells of renal tubules and induces their damage,
frequently followed by apoptosis [36,37]. We document that
one of the consequences of this acute renal injury is a
significant inhibition of [3H]thymidine incorporation into
DNA (Table 1). The above decrease in DNA synthesis
evoked by cisplatin, consistent with the suppression of cell
proliferation in the drug-injured kidney, is in marked contrast
with the proliferative response induced by antifolate CB 3717
[30]. Reduced thymidine incorporation is not accompanied
by an increase in kidney weight during the first 2 days of drug
treatment; an increase of 11.7% is observed only after 3 days
(Table 1). This enlargement of kidneys might indicate a
delayed start of the repair processes in cisplatin-injured
kidney. However, inhibition of DNA synthesis observed at
all time points rather contradicts the above suggestion.
3.2. Cisplatin up-regulates polyamine biosynthesis and
catabolism
To study polyamine biosynthesis and interconversion/
degradation in cisplatin-injured kidney, the expression of
two enzymes crucial for the above processes—ODC and
SSAT—was examined. The time course analysis of the
activity of both enzymes and their mRNA levels, shown in
Table 2, reveals their significant but differential up-regula-
tion. Thus, ODC activity, very low in control kidneys,
increases up to 15-fold 48 h after cisplatin injury and
decreases thereafter. The kinetics of induction of SSAT
activity is different—it increases gradually up to twofoldTable 1
DNA synthesis and kidney weight in cisplatin-injured mouse kidney model
Cisplatin
treatment
(days)
[3H]Thymidine
incorporation
[% control]
P Relative kidney
weight
P
0 100.0F19.3 (20) – 1.20F0.10 (40) –
1 n.d. 1.21F0.12 (20) NS
2 58.7F13.8 (10) <0.0001 1.26F0.17 (44) NS
3 72.2F25.6 (16) <0.001 1.34F0.17 (18) <0.01
[3H]Thymidine (i.p., 10 mg/kg, 0.67 MBq/25 g) was administered for 1 h.
[3H]Thymidine incorporation in control was 792F121 (n=7) (dpm/100 mg
wet weight). Relative kidney weight is expressed as percentage of body
weight in the first day of experiment. The results are expressed as
meansFS.D., the number of mice is given in parentheses. The data were
processed by the Mann–Whitney test; P values were calculated compared
with the control. NS—not significant, n.d.—not determined.during the first 24 h and remains at this elevated level for up
to 72 h.
The transcript level of both ODC and SSAT is increased
significantly by cisplatin. However, while ODC mRNA
induction is manifoldly lower than the augmentation in
enzyme activity, SSAT mRNA expression is up-regulated
to a level comparable with SSAT activity (Table 2, Fig. 1).
3.3. Cisplatin modulates testosterone-affected ODC and
SSAT expression
As shown previously, in mouse kidney, testosterone exerts
significant effects on the expression of both enzymes con-Fig. 1. Cisplatin differentially modulates testosterone-induced ODC and
SSAT mRNA expression (Northern blot analysis). Each lane represents
RNA from an individual mouse. Testosterone was injected for 5 days,
cisplatin for 2 days. The relative numerical values for ODC mRNA are
given in Table 3 and for SSAT mRNA in Fig. 2.
Table 3
Cisplatin negatively regulates testosterone-induced ODC activity and
mRNA
Treatment ODC activity
(fold increase)
ODC mRNA
(fold increase)
Control 1.00F0.70 (23) 1.00F0.42 (8)
Testosterone 225.93F34.58 (10) 9.50F3.78 (8)
Cisplatin 14.34F2.94 (8) 1.57F0.63 (8)
Testosterone+cisplatin 75.49F34.91 (9) 6.17F4.99 (8)
Testosterone was injected for 5 days, cisplatin for 2 days. The results are
expressed as meansFS.D.; the number of mice is given in parentheses.
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The negligible renal ODC activity can be induced about 870-
fold by the androgen testosterone and to a smaller extent (up
to 15-fold) by cisplatin (Table 3). However, when the two
inducers, testosterone and cisplatin, are given sequentially for
5 and 2 days, respectively (at concentrations evoking the
highest ODC induction), the ODC activity is decreased
highly significantly (P<0.0001 versus testosterone) to
33.4% of the activity induced by the androgen alone (Table
3). This antagonism between androgen and cisplatin in the
regulation of ODC expression is also visible at the level of
ODC transcript. Thus, the ODC mRNA content, augmented
up to 10-fold by testosterone, decreases to 64.9% (P<0.05
versus testosterone) when cisplatin is applied subsequently to
the androgen treatment (Table 3, Fig. 1A).
The effects of cisplatin on renal ODC activity in male
mice confirm indirectly the above observations. The male
kidneys, owing to the elevated level of endogenous testos-
terone, are characterized by 26-fold higher basal ODC
activity and nearly fourfold higher ODC transcript level
than female kidneys [39]. Cisplatin injected to male mice forFig. 2. Cross-talk between testosterone- and cisplatin-activated pathways
results in down-regulation of SSAT activity but up-regulation of SSAT
mRNA. Testosterone was injected for 5 days, cisplatin for 2 days. The
results are expressed as meansFS.D.; each experimental group consisted of
8–15 mice. The data were processed by the Mann–Whitney test.2 days increases renal ODC activity, however, the induction,
equal to 3.68F1.04 (n=14), P<0.0001, is severalfold lower
than in females.
The expression of SSAT is significantly but differentially
modulated by testosterone, the activity being down-regulat-
ed and mRNA up-regulated by this androgen [38]. As in the
case of ODC, testosterone also affects SSAT response to
cisplatin but the modulation of the activity and the transcript
level is different (Figs. 1 and 2). Thus, sequential treatment
of mice with testosterone and cisplatin (for 5 and 2 days,
respectively) evokes an increase in SSAT mRNA level, the
effect of both inducers being almost additive. This is in
contrast with SSAT activity that decreases below control
level under these conditions (Fig. 2).
It is evident, therefore, that androgen- and cisplatin-
activated pathways are not independent and their cross-talk
results in the modulation of ODC and SSAT expression.
3.4. Cisplatin effect on HGF and c-Met mRNA expression
Previously we have shown that in folate/antifolate-in-
jured kidneys, HGF/c-Met signalling pathway is severalfoldFig. 3. Time course of expression of HGF mRNA (z), c-Met mRNA (.),
c-Myc mRNA (n) and ODC activity (4) in (A) CB 3717- and (B)
cisplatin-injured kidney. Data for HGF and c-Met mRNAs 1–24 h after CB
3717 administration taken from Ref. [39] and for ODC activity time course
in (A) taken from Ref. [30]. The results are expressed as means; each
experimental group consisted of 8–15 mice.
Table 4
Differential kinetics and level of c-Myc mRNA expression induced by
cisplatin and by CB 3717
Time Relative values of c-Myc mRNA
(h)
Cisplatin P CB 3717 P
0 1.00F0.41 (11) 1.00F0.20 (11) –
1 1.93F1.48 (10) NS 1.92F0.80 (5) <0.01
3 3.91F2.16 (10) <0.001 2.71F1.09 (6) <0.01
6 3.19F2.10 (9) <0.05 6.48F2.79 (6) <0.01
12 2.88F1.01 (6) <0.0001 n. d.
24 3.63F2.02 (8) <0.0001 13.39F5.69 (11) <0.0001
48 4.32F2.54 (10) <0.0001 6.92F3.45 (7) <0.001
72 7.67F4.43 (8) <0.0001 3.26F2.04 (8) <0.01
The results of Northern blot analysis are expressed as meansFS.D.; the
number of mice is given in parentheses. The data were processed by the
Mann–Whitney test; P values were calculated compared with the control;
NS—not significant, n.d.—not determined.
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however, in a different way. The level of HGF mRNA is not
significantly changed when examined from 1 h up till 48
h after cisplatin treatment. Its significant increase is ob-
served as late as after 72 h (3.35F2.55 (n=8), P<0.01) (Fig.
3A). At this time point, HGF transcript level is augmented
by antifolate to a similar degree (2.85F2.02 (n=11),
P<0.01), (Fig. 3B).
In contrast with antifolate/folate, cisplatin does not in-
crease, but on the contrary, significantly reduces c-Met
mRNA expression. This decrease, observed already after 1
h, persists up to 12 h (Figs. 3A and 4) and can be also seen
after 1 day, while after 2 days as well as after 3 days only
nonsignificant changes are found.
3.5. Cisplatin and antifolate CB 3717 up-regulate c-Myc
mRNA expression
CB 3717 and cisplatin up-regulate c-Myc mRNA ex-
pression but the kinetics of the induction and its extent are
noticeably different (Table 4, Fig. 3). In both experimental
models, the induction of c-Myc transcript is observed as
early as after 1 h and remains at that level after 3 h.
However, afterwards antifolate evokes a sharp increase in
c-Myc m RNA, peaking at day 1 and decreasing after 2 and
3 days. In contrast, cisplatin-induced c-Myc mRNA expres-
sion stays at the elevated level from 3 h to 2 days and
reaches the highest level after 3 days.4. Discussion
In the present study, we have addressed three main
issues: the in vivo modulation of polyamine biosynthesis
and degradation in cisplatin-injured mouse kidney, theFig. 4. Cisplatin down-regulates c-Met mRNA expression (Northern blot
analysis). Each lane represents RNA from an individual mouse. Results are
expressed as meansFS.D.; the number of mice is given in parentheses. The
data were processed by the Mann–Whitney test; P values were calculated
compared with the control.cross-talk between cisplatin- and testosterone-activated
pathways and their effect on polyamine metabolism, and
the influence of cisplatin on HGF/c-Met signalling and c-
Myc mRNA expression.
Our results document that cisplatin belongs to these
nephrotoxic drugs that are able to modulate polyamine
metabolism in vivo. As we have found out, its administra-
tion to mice causes considerable increase in the expression
of renal ODC and SSAT. However, the response of activity
and transcript level of both examined enzymes to cisplatin is
not similar, pointing to the differential regulation of their
expression. Thus, cisplatin-induced ODC activity is sever-
alfold higher than that of ODC mRNA, and in this respect
resembles the effect of antifolate CB 3717 on ODC expres-
sion [40]. This is in contrast with SSAT expression up-
regulated by cisplatin where the increase of activity and
mRNA is comparable.
CB 3717, as we have shown previously, also increases
renal polyamine biosynthesis and interconversion [30,38].
However, while CB 3717-induced kidney injury leads to
regenerative kidney hyperplasia as documented by en-
hanced incorporation of thymidine into DNA and to the
increase in kidney weight [30], cisplatin decreases renal
DNA synthesis. Nevertheless, it is to be noted that morpho-
logical alterations and repair reaction following cisplatin-
induced nephrotoxic injury are dose- and time-dependent
[41]. A similar time course of SSAT activity in cisplatin-
damaged kidney and in thymocytes undergoing apoptosis
[42] points to apoptosis as a consequence of cisplatin-
induced injury. These results suggest that renal proximal
tubule damage induced by cisplatin at the dose applied is
not associated with the regeneration but rather with apopto-
sis and necrosis, as shown by others (e.g. Refs. [3,36,37]).
However, we have not confirmed the earlier report that
carnitine protects kidney against mitochondria-dependent
apoptosis induced by cisplatin in rats [43]. Carnitine (200
mg/kg, s.c.), when administered to mice 30 min prior to
cisplatin, evoked only statistically nonsignificant 10% de-
crease in drug-induced ODC activity (used as a marker of
A. Stachurska et al. / Biochimica et Biophysica Acta 1689 (2004) 259–266264kidney injury; data not shown). It appears, therefore, that in
mouse kidney, DNA, not mitochondria, is the critical target
for cisplatin toxic effect.
Previously we have reported a substantial negative reg-
ulation of androgen-induced ODC gene expression as a
result of the cross-talk between signalling pathways activat-
ed by testosterone and by HGF in antifolate/folate-injured
kidney [39]. In this study, we further document that the
androgen/androgen receptor pathway and a signal transduc-
tion pathway(s) induced by damage to renal tubules evoked
by cisplatin do not act independently but cross-talk. Thus,
cisplatin, similarly to CB 3717 [39], significantly modulates
renal polyamine biosynthesis and degradation in mice pre-
treated with testosterone. Namely, it decreases testosterone-
induced renal expression of ODC both at the activity and
mRNA level. Cisplatin also regulates SSAT gene expression
by increasing renal SSAT activity, lowered by testosterone
treatment, nearly to the level found in control mice. In
contrast with SSAT activity, SSAT mRNA is induced by
testosterone [38]. Cisplatin that also evokes pronounced
elevation of SSAT mRNA level, when administered together
with the androgen, further increases SSAT mRNA expres-
sion. Thus, the response of SSAT mRNA to cisplatin and
testosterone (this study) as well as to antifolate [38] appears
to be different from that of SSAT activity. A similar
observation—a higher up-regulation of the SSAT transcript
than of SSAT activity—was already reported before (e.g.
Refs. [44,45]). Although the molecular mechanism of this
differential regulation of SSAT expression is up till now not
elucidated, it indicates that the processes of SSAT protein
translation and/or degradation are affected, and stresses the
importance of SSAT posttranscriptional regulation.
Although signalling pathways activated in cisplatin- as
well as in antifolate/folate-damaged kidney interact with
testosterone-activated signalling to negatively regulate ODC
expression, they appear to differ in both experimental
models. In contrast with the documented induction of the
expression of HGF/c-Met in kidney injured by antifolate or
folate [39,46], we have found that in cisplatin-damaged
mouse kidney, HGF/c-Met mRNA expression is affected
only slightly. Fig. 3 shows the collective data to compare the
HGF, c-Met and c-Myc mRNAs, and ODC activity in the
two experimental models after exposure to both nephrotoxic
drugs—antifolate and cisplatin. While HGF expression
remains unchanged at the early time points and is elevated
not earlier than 3 days after cisplatin application, the
expression of c-Met mRNA is not increased but significant-
ly reduced (Fig. 3B). These changes in HGF/c-Met signal-
ling evoked by cisplatin are diametrically opposed to those
found in antifolate/folate-injured kidney (Fig. 3A). Howev-
er, they do not definitively exclude the possibility that HGF/
c-Met pathway mediates the effects of cisplatin on renal
polyamine metabolism, because it has been reported that
cisplatin can activate a growth factor receptor (EGFR) and
its downstream effectors without having any effect on its
expression [47].The in vivo and in vitro beneficial effect of HGF,
preventing cisplatin-induced injury and cytotoxicity, is well
established. Thus, exogenous HGF prevents acute renal
failure evoked by cisplatin and accelerates kidney regener-
ation in mice [48]. Similarly, pretreatment of cells with HGF
[49] or a constitutive expression of this renotropic factor
[50] partially abrogates the cytotoxic effects of cisplatin and
also results in resistance to cisplatin-induced cell death.
Cisplatin as a genotoxic agent activates multiple signal-
ling pathways involved in coordinating cellular responses to
stress. This drug triggers the activation of JNK, p38 and
ERK—members of the MAPK family promoting apoptotic
cell death [51–53]. Moreover, as mentioned above, the
signals generated by cisplatin-induced DNA damage can
activate, in a ligand-independent way, membrane receptor
EGFR, believed to promote cell survival [47].
c-Myc protooncogene is implicated in diverse physio-
logical processes such as cell growth, proliferation, differ-
entiation and cell death. Numerous reports are also devoted
to the still controversial role of c-Myc in drug-induced
apoptosis and cell susceptibility to anticancer agents, cis-
platin included (e.g. Refs. [54–56]). Accordingly, studies
using c-Myc promoter have shown that DNA damage
induced by cisplatin may specifically up-regulate the ex-
pression of c-myc gene [57].
The involvement of c-Myc in the regulation of poly-
amine biosynthesis is well established since ODC is tran-
scriptionally regulated by c-Myc, being one of the first
identified Myc target genes [58,59]. In this paper, we
document that c-Myc mRNA level and ODC activity
increase in the kidney after cisplatin as well as antifolate
treatment. Although the considerable induction of c-Myc
mRNA occurs in both experimental models, it should be
stressed that the kinetics and the degree of cisplatin and
antifolate induction of c-Myc transcript differ considerably.
When estimating a temporal association between c-Myc and
ODC induction, we have found that the induction of ODC
activity after antifolate insult paralleled the increase in c-
Myc mRNA (Fig. 3A). In contrast, in cisplatin-injured
kidney, c-Myc mRNA remained elevated (and even further
increased) while ODC activity began to decrease (Fig. 3B).
It appears, therefore, that the presented data are in favour of
the involvement of c-Myc in the modulation of its target
gene, ODC, in the kidney damaged by antifolate as sug-
gested before [39], but do not support the role of this
transcription factor in the regulation of ODC expression in
cisplatin-injured kidney.Acknowledgements
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